The MTNAP1 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma cell line, designed to disrupt the MTNAP1 (Mitochondrial Nucleoid-Associated Protein 1) gene. This polyclonal population provides a heterogeneous loss-of-function model without clonal selection, offering a robust tool for studying the consequences of MTNAP1 deficiency in a cancer-relevant context. The knockout model aids in elucidating the role of MTNAP1 in mitochondrial nucleoid organization and mtDNA maintenance.
The HT29 cell line originates from a primary colorectal adenocarcinoma and is widely used as a model for colorectal cancer biology and intestinal epithelial differentiation. Under appropriate culture conditions, HT29 cells can differentiate into enterocyte-like and mucus-secreting cells, making them valuable for studying cellular differentiation processes. Their well-characterized genetic background and reproducible growth characteristics establish them as a reliable host for gene knockout studies.
MTNAP1 is a mitochondrial protein that localizes to nucleoids, where it plays a critical role in organizing and maintaining mitochondrial DNA (mtDNA). It facilitates proper mitochondrial gene expression and respiratory chain function by interacting with key components of the mtDNA replication and transcription machinery, including TFAM, POLG, mtSSB, POLRMT, and members of the MTERF family. Upstream, MTNAP1 expression and activity are regulated by energy deprivation signals and transcription factors such as PGC-1??, NRF1, and NRF2, positioning it within the AMPK-mediated metabolic signaling network. Downstream, MTNAP1 promotes mtDNA replication, mitochondrial transcription, OXPHOS complex assembly, and mitochondrial translation. Representatively, the pathway includes PGC-1??, NRF1, TFAM, MTNAP1, mtDNA, and OXPHOS complexes I?CV.
In the HT29 colorectal cancer cell model, knockout of MTNAP1 is expected to impair mitochondrial biogenesis and energy metabolism, as MTNAP1 deficiency disrupts nucleoid architecture and mtDNA maintenance. Such metabolic perturbation may influence cancer cell proliferation and survival, particularly given the reliance of many colorectal tumors on oxidative phosphorylation. This polyclonal knockout population thus enables investigation into how mitochondrial dysfunction intersects with oncogenic signaling, metabolic reprogramming, and sensitivity to therapeutic agents targeting mitochondrial pathways.
Researchers can employ these MTNAP1 knockout HT29 polyclonal cells in a variety of assays to probe mitochondrial biology in colorectal cancer. Representative applications include quantifying mtDNA copy number via qPCR, assessing mitochondrial respiration using Seahorse respirometry, profiling OXPHOS complex expression by Western blotting, and evaluating apoptosis through Annexin V staining. Additionally, cell proliferation assays (e.g., MTS, BrdU), mitochondrial membrane potential measurements with JC-1 dye, and transcriptomic analyses by RNA-seq can elucidate metabolic and functional consequences of MTNAP1 loss. These tools support studies on mitochondrial dysfunction, drug sensitivity, and cancer metabolic reprogramming. For further details or to request a quote, please contact Ascent Research.
